Adeno-associated virus (AAV) clade f vector and uses therefor

Patent metadata

Field	Value
Publication number	US-11827906-B2
Application number	US-201816487674-A
Country	US
Kind code	B2
Filing date	Feb 27, 2018
Priority date	Feb 28, 2017
Publication date	Nov 28, 2023
Grant date	Nov 28, 2023

Abstract

A recombinant adeno-associated virus (rAAV) vector comprising an AAVhu68 capsid produced in a production system comprising a nucleotide sequence of SEQ ID NO: 1, or a sequence at least 75% identical thereto which encodes SEQ ID NO:2. The AAVhu68 capsid comprises subpopulations of highly deamidated asparagine residues in asparagine-glycine pairs in the amino acid sequence of SEQ ID NO: 2. Also provided are compositions containing the rAAV and uses thereof. Additionally, rAAV having an engineered AAV capsid comprising at least one subpopulation of vp1 or vp2 proteins having a Val at amino acid position 157 with reference to the AAVhu68 vp1 numbering are provided.

First claim

The invention claimed is:

1. A recombinant adeno-associated virus (rAAV) which has an AAVhu68 capsid and a vector genome, wherein the AAV hu68 capsid comprises a heterogenous population of AAVhu68 vp1 proteins, a heterogenous population of AAVhu68 vp2 proteins; and a heterogenous population of AAVhu68 vp3 proteins comprising amino acid residues 1 to 736 (vp1), amino acid residues 138 to 736 (vp2), and amino acid residues 203 to 736 (vp3) of SEQ ID NO: 2, respectively, with amino acid modifications,
wherein the heterogenous populations of AAVhu68 vp1 proteins, AAVhu68 vp2 proteins and AAVhu68 vp3 proteins contain amino acid modifications comprising 50% to 100% deamidation in at least two asparagines (N) in asparagine-glycine pairs in SEQ ID NO: 2 in two or more of asparagines (N) at positions N57, N329, N452, and/or N512 based on the numbering of the encoded AAVhu68 VP1 amino acid sequence (SEQ ID NO: 2) as determined using mass spectrometry and optionally further comprising subpopulations of AAVhu68 vp1 proteins, AAVhu68 vp2 proteins, and AAVhu68 vp3 proteins comprising other deamidated amino acids, wherein the deamidation results in an amino acid change, wherein the deamidated asparagines are deamidated to aspartic acid, isoaspartic acid, an interconverting aspartic acid/isoaspartic acid pair, or combinations thereof,
wherein the subpopulations of AAVhu68 VP1 proteins, AAVhu68 VP2 proteins and AAVhu68VP3 proteins further comprise one or more of:
(a) at least 65% of asparagines (N) in a position N57 of the vp1 proteins are deamidated, based on the numbering of SEQ ID NO:2;
(b) at least 75% of N in position N329 of the vp1, v2 and vp3 proteins are deamidated, based on the residue numbering of the amino acid sequence of SEQ ID NO: 2,
(c) at least 50% of N in position N452 of the vp1, v2 and vp3 proteins are deamidated, based on the residue numbering of the amino acid sequence of SEQ ID NO: 2; and/or
(d) at least 75% of N in N512 of the vp1, v2 and vp3 proteins are deamidated, based on the residue numbering of the amino acid sequence of SEQ ID NO: 2,
wherein the heterogenous population of AAVhu68 vp1 proteins comprise glutamic acid at position 67 based on the numbering of SEQ ID NO:2 and the heterogenous population of AAVhu68vp1 and AAVhu68 vp2 proteins comprise valine at position 157, based on the numbering of the vp1 capsid of SEQ ID NO:2; and
the vector genome comprising a nucleic acid molecule comprising an AAV 5′ inverted terminal repeat (ITR), a nucleic acid sequence encoding a product operably linked to sequences which direct expression of the product, and an AAV 3′ ITR, wherein the 5′ and 3′ ITRs are from a source other than AAVhu68, provided that the vector genome does not comprise a survival motor neuron (SMN) protein coding sequence or a coding sequence for an anti-influenza immunoglobulin construct.

2. The rAAV according to claim 1 , wherein the rAAVhu68 capsid comprises a subpopulation of vp1 in which 75% to 100% of the N at position 57 of the vp1 proteins, based on the numbering of SEQ ID NO:2, are deamidated as determined using mass spectrometry.

3. The rAAV according to claim 1 , wherein the rAAVhu68 capsid comprises subpopulations of vp1 proteins, vp2 proteins, and/or vp3 proteins in which 75% to 100% of the N at position 329, based on the numbering of SEQ ID NO:2, are deamidated as determined using mass spectrometry.

4. The rAAV according to claim 1 , wherein the rAAVhu68 capsid comprises subpopulations of vp1 proteins, vp2 proteins, and/or vp3 proteins in which 75% to 100% of the N at position 452, based on the numbering of SEQ ID NO:2, are deamidated as determined using mass spectrometry.

5. The rAAV according to claim 1 , wherein the rAAVhu68 capsid comprises subpopulations of vp1 proteins, vp2 proteins, and/or vp3 proteins in which 75% to 100% of the N at position 512, based on the numbering of SEQ ID NO:2, are deamidated.

6. The rAAV according to claim 1 , wherein the nucleic acid sequence encoding the proteins is SEQ ID NO: 1, or a sequence at least 80% to at least 99% identical to SEQ ID NO: 1 which encodes the amino acid sequence of SEQ ID NO:2.

7. The rAAV according to claim 6 , wherein the sequence is at least 80% to 97% identical to SEQ ID NO: 1.

8. The rAAV according to claim 1 , wherein the rAAVhu68 capsid comprises 50% to 100% deamidation in each of N57, N329, N452, and N512, and optionally further comprise subpopulations of vp1, vp2 and/or vp3 proteins which further comprise 1% to about 40% deamidation in at least one or more of positions N94, N113, N252, N253, Q258, N270, N303, N304, N305, N319, N328, N336, N409, N410, N477, N515, N598, Q599, N628, N651, N663, N709, or combinations thereof, based on the amino acid numbering of SEQ ID NO: 2.

9. The rAAV according to claim 1 , wherein the rAAVhu68 capsid vp1, vp2 and/or vp3 proteins further comprise one or more modifications selected from one or more of the following: acetylated lysine, phosphorylated serine and/or threonine, isomerized aspartic acid, oxidized tryptophan and/or methionine, or an amidated amino acid.

10. The rAAV according to claim 1 , wherein the AAV ITR sequences are a 5′ ITR and a 3′ ITR from an AAV2 source.

11. A composition comprising a mixed population of recombinant adeno-associated virus hu68 (rAAVhu68), wherein each of the rAAVhu68 is independently selected from an rAAV according to claim 1 .

12. The composition according to claim 11 , wherein the AAV ITR sequences are a 5′ ITR and a 3′ ITR from an AAV2.

13. The composition according to claim 11 , wherein the composition is formulated for intrathecal delivery and the vector genome comprises a nucleic acid sequence encoding a product for delivery to the central nervous system.

14. The composition according to claim 11 , wherein the composition is formulated for intravenous delivery.

15. The composition according to claim 11 , wherein the composition is formulated for intranasal or intramuscular delivery.

16. A recombinant adeno-associated virus (rAAV) which comprises an AAVhu68 capsid comprising:
(A) a heterogenous population of AAVhu68 vp1, AAVhu68vp2 and AAVhu68vp3 proteins produced by expression from a nucleic acid molecule having a nucleic acid sequence encoding the amino acid sequence of 1 to 736 of SEQ ID NO:2,
wherein the heterogenous population of AAVhu68 vp1 proteins, AAVhu68 vp2 proteins, and AAVhu68 vp3 proteins comprise amino acids 1 to 736 (vp1), amino acids 138 to 736 (vp2), and amino acids 203 to 736 (vp3) of SEQ ID NO: 2, respectively, with amino acid modifications comprising 50% to 100% deamidation in at least two asparagines (N)-glycine pairs in two or more of N57, N329, N452, and/or N512 of SEQ ID NO: 2 as determined using mass spectrometry and optionally further comprising subpopulations of AAVhu68 vp1 proteins, AAVhu68 vp2 proteins and AAVhu68 vp3 proteins comprising other deamidated amino acids;
wherein the heterogenous population of AAVhu68 vp1 proteins comprise glutamic acid at position 67 based on the numbering of SEQ ID NO:2 and the heterogenous population of AAVhu68vp1 and AAVhu68 vp2 proteins comprise valine at position 157, based on the numbering of the vp1 capsid of SEQ ID NO:2; and
(B) a vector genome in the AAVhu68 capsid, the vector genome comprising a nucleic acid molecule comprising an AAV 5′ inverted terminal repeat (ITR), a nucleic acid sequence encoding a product operably linked to sequences which direct expression of the product in a target cell, and an AAV 3′ ITR, wherein the 5′ and 3′ ITRs are from a source other than AAVhu68, provided that the vector genome does not comprise a survival motor neuron (SMN) prote

Assignees

• Univ Pennsylvania

Inventors

• Wilson James M
• Wang Qiang
• Tepe April
• Turner Kevin

Classifications

• C12N2750/14143

  viral genome or elements thereof as genetic vector · CPC title

• C12N2750/14122

  New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title

• C12N2750/14121

  Viruses as such, e.g. new isolates, mutants or their genomic sequences · CPC title

• C12N15/86

  Viral vectors · CPC title

• C07K14/005

  from viruses · CPC title